Urothelial Cancer

Roger Li, MD, discusses the implications of a post hoc analysis of the KEYNOTE-057 trial in BCG-unresponsive, high-risk non–muscle-invasive bladder cancer.

Karl Semaan, MD, MSc, discusses the clinical advantages of liquid biopsy over tissue biopsies in detecting sarcomatoid renal cell carcinoma.

China’s National Medical Products Administration has approved enfortumab vedotin for adult patients with locally advanced or metastatic urothelial cancer.

Bradley McGregor, MD, discusses the clinical implications of the DAD-IO trial in patients with metastatic urothelial carcinoma.

Neil J. Shah, MBBS, discusses treatment patterns and clinical outcomes in metastatic renal cell carcinoma after an immuno-oncology/TKI combination.

A new drug application has been submitted to the FDA for UGN-102 inlow-grade, intermediate-risk non–muscle-invasive bladder cancer.

Roger Li, MD, details a post hoc analysis of patients with BCG-unresponsive non–muscle-invasive bladder cancer who did not respond to pembrolizumab.

The Nectin-4–directed antibody-drug conjugate 9MW2821 has received breakthrough therapy designation in China for pretreated, advanced urothelial carcinoma.

Enfortumab vedotin plus pembrolizumab improved survival vs chemotherapy with no QOL detriment in previously untreated metastatic urothelial cancer.

Joshua Linscott, MD, PhD, discusses a study investigating the use of utDNA to predict MRD prior to rTURBT in NMIBC.

Drs Park and Grivas discuss bladder cancer treatment updates, including results from the SunRISe-1 trial of TAR-200 plus cetrelimab in NMIBC.

Valisha Shah, MS, discusses the observed association between clonal hematopoiesis and RCC with cardiovascular diseases.

Roger Li, MD, discusses the efficacy of bladder-sparing therapy after progression on pembrolizumab in patients with BCG-unresponsive, high-risk NMIBC.

First-line avelumab maintenance demonstrated efficacy and manageable toxicity in patients with low tumor burden advanced urothelial carcinoma.

The CHMP has recommended pembrolizumab plus enfortumab vedotin-ejfv in frontline unresectable or metastatic urothelial carcinoma.

Drs Park and Sonpavde discuss findings from the phase 1 DAD trial, as well as a schema for the frontline management of metastatic urothelial carcinoma. 

IDE937 produced responses in patients with advanced urothelial cancer or non–small cell lung cancer harboring MTAP deletions.

Antonio Cigliola, MD, discusses the evaluation of neoadjuvant sacituzumab govitecan in patients with muscle-invasive bladder cancer.

Tazemetostat plus pembrolizumab was tolerable in platinum-exposed or -ineligible advanced urothelial carcinoma.

The EMA's CHMP has adopted a positive opinion regarding erdafitinib in patients with FGFR3+ unresectable or metastatic urothelial carcinoma.

Bradley McGregor, MD, on the ongoing evaluation of sacituzumab govitecan plus enfortumab vedotin with or without pembrolizumab in urothelial carcinoma.

Perioperative durvalumab demonstrated a statistically significant improvement in EFS and OS in muscle-invasive bladder cancer.

Fernando C. Maluf, MD, PhD discusses the efficacy of platinum-based chemotherapy plus pembrolizumab in advanced penile squamous cell carcinoma.

Michael Serzan, MD, discusses the use of botensilimab/balstilimab in the treatment of patients with advanced renal cell carcinoma.

Roger Li, MD, discusses patient outcomes from the KEYNOTE-057 trial in BCG–unresponsive, high-risk non–muscle-invasive bladder cancer.